Release Summary

Chugai's ACTEMRA®/RoACTEMRA® receives Breakthrough Therapy Designation from US FDA for Giant Cell Arteritis. This is the fifth breakthrough therapy designation granted for a Chugai originated drug.

Chugai Pharmaceutical Co., Ltd.